Next Article in Journal
Molecular and Biochemical Basis of Minocycline-Induced Hyperpigmentation—The Study on Normal Human Melanocytes Exposed to UVA and UVB Radiation
Next Article in Special Issue
Usher Syndrome in the Inner Ear: Etiologies and Advances in Gene Therapy
Previous Article in Journal
Molecular Analysis of ZNF71 KRAB in Non-Small-Cell Lung Cancer
Previous Article in Special Issue
Identifying Methylation Patterns in Dental Pulp Aging: Application to Age-at-Death Estimation in Forensic Anthropology
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 7
10.3390/ijms22073754
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

DNA Methylation Patterns Correlate with the Expression of SCNN1A, SCNN1B, and SCNN1G (Epithelial Sodium Channel, ENaC) Genes

by
Silvia Pierandrei
1,
Gessica Truglio
1,
Fabrizio Ceci
1,
Paola Del Porto
2,
Sabina Maria Bruno
1,
Stefano Castellani
3,
Massimo Conese
4,
Fiorentina Ascenzioni
2,* and
Marco Lucarelli
1,5,*
1
Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Roma, Italy
2
Department of Biology and Biotechnology “Charles Darwin”, Sapienza University of Rome, Via dei Sardi 70, 00185 Roma, Italy
3
Department of Biomedical Sciences and Human Oncology, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy
4
Department of Medical and Surgical Sciences, University of Foggia, Via Napoli 121, 71122 Foggia, Italy
5
Pasteur Institute, Cenci Bolognetti Foundation, Sapienza University of Rome, Viale Regina Elena 291, 00161 Roma, Italy
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(7), 3754; https://doi.org/10.3390/ijms22073754
Submission received: 28 January 2021 / Revised: 12 March 2021 / Accepted: 23 March 2021 / Published: 4 April 2021
(This article belongs to the Collection Feature Papers in Molecular Genetics and Genomics)
Browse Figures
Review Reports Versions Notes

Abstract

:
The interplay between the cystic fibrosis transmembrane conductance regulator (CFTR) and the epithelial sodium channel (ENaC) in respiratory epithelia has a crucial role in the pathogenesis of cystic fibrosis (CF). The comprehension of the mechanisms of transcriptional regulation of ENaC genes is pivotal to better detail the pathogenic mechanism and the genotype–phenotype relationship in CF, as well as to realize therapeutic approaches based on the transcriptional downregulation of ENaC genes. Since we aimed to study the epigenetic transcriptional control of ENaC genes, an assessment of their expression and DNA methylation patterns in different human cell lines, nasal brushing samples, and leucocytes was performed. The mRNA expression of CFTR and ENaC subunits α, β and γ (respectively SCNN1A, SCNN1B, and SCNN1G genes) was studied by real time PCR. DNA methylation of 5′-flanking region of SCNN1A, SCNN1B, and SCNN1G genes was studied by HpaII/PCR. The levels of expression and DNA methylation of ENaC genes in the different cell lines, brushing samples, and leukocytes were very variable. The DNA regions studied of each ENaC gene showed different methylation patterns. A general inverse correlation between expression and DNA methylation was evidenced. Leukocytes showed very low expression of all the 3 ENaC genes corresponding to a DNA methylated pattern. The SCNN1A gene resulted to be the most expressed in some cell lines that, accordingly, showed a completely demethylated pattern. Coherently, a heavy and moderate methylated pattern of, respectively, SCNN1B and SCNN1G genes corresponded to low levels of expression. As exceptions, we found that dexamethasone treatment appeared to stimulate the expression of all the 3 ENaC genes, without an evident modulation of the DNA methylation pattern, and that in nasal brushing a considerable expression of all the 3 ENaC genes were found despite an apparent methylated pattern. At least part of the expression modulation of ENaC genes seems to depend on the DNA methylation patterns of specific DNA regions. This points to epigenetics as a controlling mechanism of ENaC function and as a possible therapeutic approach for CF.

1. Introduction

Pathogenic variants of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene, by lowering or abolishing the CFTR Cl- channel activity, cause a broad spectrum of clinical manifestations spanning from Cystic Fibrosis (CF) to the so-called CFTR related disorders (CFTR-RD) [1,2]. It has been suggested that dysfunctional CFTR impacts the activity of epithelial sodium channel (ENaC) causing an altered interaction between CFTR and ENaC that, in respiratory epithelia, contributes to both CF and CFTR-RD [3,4,5,6,7,8]. Wild-type CFTR inhibits ENaC function by impeding its proteolytic activation and reducing channel opening [9,10,11]. On the contrary, mutated CFTR is not able to protect ENaC from proteolytic cleavage and activation [10], which, in turn, results in higher Na+ absorption by epithelial cells. Through the Na+ transport across respiratory epithelium, the ENaC regulates hydration of the airways surface liquid [12,13]. Its expression in lungs has a crucial role for physiologic pulmonary function and regeneration [12]. Therefore, the coordinated transport of Cl- and Na+ mediated by CFTR and ENaC contributes to the correct hydration of human airways [14,15,16]. In addition, this functional network originates a complex relationship between genotype and phenotype in CF [17,18,19,20] and impact on its diagnosis, prognosis, and therapy [2,21,22].
ENaC is composed of the α, β and γ subunits, coded by the genes for the sodium channel epithelial 1 subunits α, β and γ, respectively SCNN1A [23], SCNN1B, and SCNN1G [24], whose expression appears to be under the transcriptional control of DNA methylation. The SCNN1A gene has a high density of CpG sites [25], whereas SCNN1B and SCNN1G genes have, respectively, one [26] and two [27,28] CpG islands. In effect, DNA methylation-dependent transcriptional changes of the SCNN1B [29,30,31] and SCNN1G [28] gene have been described, suggesting that this regulatory mechanism can be targeted to control ENaC expression and activity. Indeed, the targeting of methylation, at both the DNA [28] (with consequent chromatin remodeling) and protein [32] (affecting Na+ transport) level, appears to be a promising approach, although barely explored until now. In general, experimental evidence points to the targeting of ENaC as a potential therapy for CF [33,34,35]. Accordingly, it has been shown that the silencing of the α subunit by lentiviral small hairpin RNA caused a significant reduction of the ENaC activity supporting the notion that gene expression inhibition of one out of the three ENaC subunits is sufficient to dampen ENaC activity [36]. Although other anti-ENaC therapeutic tools have been proposed, most of them failed and new approaches are needed [37,38,39,40,41,42,43,44,45].
With the aim of better understanding the mechanisms of transcriptional regulation of ENaC genes, in this work, we studied the expression level and the associated DNA methylation pattern of SCNN1A, SCNN1B, and SCNN1G genes, in different human cell line, nasal brushing samples, and leukocytes. A better comprehension of the transcriptional regulation mechanisms of these genes may better clarify the genotype–phenotype relationship in CF, enhance our diagnostic and prognostic ability, as well as open the way to a realistic therapeutic intervention based on epigenetic silencing of ENaC genes.

2. Results

2.1. Expression of ENaC Genes

The cellular models selected in this study (described in Materials and Methods) were first assessed for CFTR expression by real time PCR. CFTR expression was high in 16HBE, moderate or low in H441, MCF10A and CFBE, and very low in HaCaT (Figure S1A). Dexamethasone treatment increased CFTR expression in H441, while it caused a reduction in MCF10A (Figure S1B). The analysis of ex vivo samples showed a significant expression of CFTR only in nasal brushing and, at a lower extent, in monocytes, whereas in the other peripheral blood cells the expression was low or very low (Figure S1C).
Next, we assessed the expression of ENaC genes by real time PCR. The results showed high expression of the SCNN1A gene in H441 and HaCaT, moderate expression in MCF10A and 16HBE, whereas CFBE showed low expression (Figure 1A). As expected, dexamethasone treatment increased SCNN1A gene expression in both H441 and MCF10A (Figure 1B). The highest level of expression of SCNN1A gene was evidenced in nasal brushing, whereas it was moderate or low in leukocytes (Figure 1C).
The gene expression of SCNN1B resulted generally lower than SCNN1A gene (as can be seen from the extension of y-axis in Figure 1D,F). Indeed, SCNN1B gene was moderately expressed in H441, very low expressed in MCF10A, 16HBE, and CFBE, and undetectable in HaCat (Figure 1D). Similar to the SCNN1A gene, dexamethasone treatment increased the expression of the SCNN1B gene in both H441 and MCF10A (Figure 1E). As for the SCNN1A, the nasal brushing samples showed the highest expression of SCNN1B gene, whereas its expression was almost undetectable in leukocytes (Figure 1F).
The gene expression of SCNN1G was lower than SCNN1B gene (as can be seen from the extension of y-axis in Figure 1G,I). In particular, SCNN1G was moderately expressed in H441, low expressed in MCF10A and CFBE, and very low expressed in 16HBE and HaCaT (Figure 1G). An increase in expression of SCNN1G gene was induced by dexamethasone in both H441 and MCF10A (Figure 1H). Nasal brushing showed a moderate expression of SCNN1G gene, whereas a very low expression was found in leukocytes (Figure 1I).
The results obtained by real time PCR revealed that the H441 cell line showed a good expression of all the 3 ENaC genes, in the following quantitative order SCNN1A >> SCNN1B > SCNN1G. HaCaT showed a high expression of SCNN1A gene but a very low (if any) expression of SCNN1B and SCNN1G genes. Similarly, in the other cell lines (MCF10A, 16HBE, and CFBE), the most expressed ENaC gene was the SCNN1A with the expression of SCNN1B and SCNN1G genes being low or very low. In all the cell lines, the SCNN1A gene resulted to be the most expressed, although its expression in CFBE was well below to that in the other cell lines. All the 3 ENaC genes were inducible by dexamethasone in both tested cell lines (H441 and MCF10A). All the 3 ENaC genes were shown to be expressed in nasal brushing in the following quantitative order SCNN1A >> SCNN1B > SCNN1G. The expression of the SCNN1A gene in nasal brushing was the highest among all the experimental models and conditions herein tested, while the expression of all the 3 ENaC genes in leukocytes were shown to be well below to that in nasal brushing and cell lines and appreciable only for SCNN1A gene.
Data from quantitative real time PCR were also displayed by qualitative endpoint PCR and agarose gel electrophoresis, which are reported in supplementary information (CFTR, Figure S2; SCNN1A, Figure S3A–C; SCNN1B, Figure S3D–F; SCNN1G, Figure S3G–I).

2.2. Methylation of ENaC Genes

The methylation analysis was performed according to the general organization of 5′-flanking regions of ENaC genes reported in Figure S4. The analysis of the three regions containing CCGG sites (a, b and c) and one control region without CCGG sites (Control) of the 5′-flanking region of the SCNN1A gene, showed the “a” region demethylated in all the experimental conditions (Figure 2). In the cell lines (Figure 2A), the “b” and “c” regions resulted demethylated in H441, MCF10A and HaCaT cells, in which SCNN1A was highly expressed. Moreover, “b” and “c” regions resulted methylated in CFBE cells, where SCNN1A was expressed at very low levels. Also, 16HBE cells showed a methylated status in the “c” region according to their moderate SCNN1A gene expression levels. Dexamethasone treatment of H441 and MCF10A cells resulted ineffective on methylation status (Figure 2B), although stimulating SCNN1A expression. Results from nasal brushing and leukocytes showed a general methylation of both “b” and “c” regions (Figure 2C). The methylation of the “b” and “c” regions appeared well correlated with the low expression of the SCNN1A gene in leukocytes, on the contrary to nasal brushing. Overall, with the exception of nasal brushing and dexamethasone treatment, a good inverse correlation between DNA methylation and expression of the SCNN1A gene was evidenced.
The analysis of the four regions containing CCGG sites (a, b, c and d) and one control region without CCGG sites (Control) of the 5′-flanking region of the SCNN1B gene showed the “b” region demethylated and the “c” region methylated in all the experimental conditions (Figure 3). In the cell lines (Figure 3A,D), the “a” and “d” regions resulted in a general methylated pattern, well correlated with the low expression of SCNN1B gene. The methylated pattern of H441 and MCF10A cells did not change after dexamethasone treatment (Figure 3B,E), despite the increase in SCNN1B gene expression. A methylated pattern of “a” and “d” regions (in addition to the “c” region), and a concomitant low expression of SCNN1B gene, was evidenced also in nasal brushing and leukocytes. Overall, compared to the SCNN1A gene, the SCNN1B gene showed a heavier methylated pattern which correlated to a lower expression.
The analysis of the two regions containing CCGG sites (a and b) and one control region without CCGG sites (Control) of 5′-flanking of SCNN1G gene showed the “b” region demethylated in all the experimental conditions (Figure 4). In cell lines (Figure 4A,D) the “a” region resulted slightly methylated in the H441, 16HBE, CFBE, and HaCaT cells and completely demethylated in MCF10A. This partially methylated pattern resulted to be well correlated to the low expression of SCNN1G gene (comparable to that of SCNN1B gene), with the exception of the MCF10A cells. Also, for the SCNN1G gene, dexamethasone treatment did not modify the basal methylation pattern of H441 and MCF10A cells (Figure 4B,E), although SCNN1G gene expression increased after treatment. A similar partially methylated pattern of the “a” region was shown in nasal brushing and leukocytes (Figure 4C,F), and it was associated with a general low gene expression. Compared to the other two ENaC genes, SCNN1G gene showed a methylation pattern intermediate between the SCNN1A gene (the least methylated in well expressing conditions) and the SCNN1B gene (the most methylated in low expressing conditions).
The cumulative results of SCNN1A, SCNN1B and SCNN1G gene expression and DNA methylation are schematized in Figure 5A,B,C respectively.

3. Discussion

The expression levels of the SCNN1A, SCNN1B, and SCNN1G genes, in the different cellular models herein considered, well correlate with the DNA methylation pattern of the regions we have analyzed. This is demonstrated by the correlation of low expression level/high DNA methylation or high expression level/low DNA methylation. Accordingly, leukocytes showed a very low (or absent) expression of all the three genes and a DNA methylation in the regions examined. In cell lines, in particular the SCNN1A gene was shown to be the most expressed and the most demethylated, the SCNN1B gene was shown to be the least expressed and the most methylated, and the SCNN1G gene was shown to have intermediate levels of expression and methylation. Discrepant results were obtained only after dexamethasone treatment and in nasal brushing. Dexamethasone stimulated the expression of all the three ENaC genes without apparent modulation of the DNA methylation. For the SCNN1A gene this result may be explained with the completely demethylated pattern already present in basal conditions in the analyzed regions. However, in the SCNN1B and SCNN1G genes, a methylated pattern potentially editable was present in untreated cells, but no variation could be detected after dexamethasone treatment. It can be concluded that the mechanism of dexamethasone induction of ENaC gene expression does not involve the modulation of DNA methylation of the studied regions. In nasal brushing, a high expression of SCNN1A gene and moderate expression of SCNN1B and SCNN1G gene were found despite the methylated patterns. This is probably due to a mixed composition of nasal tissue where are present both expressing and non-expressing cell types: the expressing cells responsible for the expression detection and the non-expressing cells for the methylated pattern.
The DNA regions studied for methylation appeared to be not equivalent. One region of SCNN1A gene resulted always demethylated in all the samples (being the methylation of the other two regions modulated). In SCNN1B one region resulted always demethylated and another region always methylated in all the samples (being the methylation of the other two regions partially modulated, although less than in SCNN1A gene). In the SCNN1G gene one region was always demethylated and the methylation of the other region modulated. It should be taken into account that, with the method here used for methylation analysis, when the amplicon of a specific region is not present it means that at least one HpaII site is unmethylated. On the contrary, when the amplicon of a specific region is present it means that all the HpaII sites are methylated. The great differences in DNA methylation patterns of different regions found with this approach stimulates a finer analysis at single cytosine level, possibly distinguishing between CpG and non-CpG methylation [46] which was shown to be crucial in other contexts [47,48].
Our results highlight that at least part of the transcriptional control of SCNN1A, SCNN1B and SCNN1G genes is exerted by DNA methylation. This points to epigenetics as a mechanism for the regulation of expression and, finally, activity of ENaC in both physiologic and pathologic contexts. In particular, in CF, a better comprehension of the functional modulation of ENaC could help to clarify the genotype–phenotype relationship, as well as to plan innovative therapeutic approaches. The induction of methylated patterns on ENaC genes could downregulate ENaC activity, partially correcting its dysregulated over-activity due to the loss of CFTR-dependent inhibition. A more focused and high-resolution mapping of methylation of CpG and non-CpG moieties within the control regions of ENaC genes appears to be mandatory.

4. Materials and Methods

4.1. Cells and Culture Conditions

Cell lines: H441 (ATCC® HTB-174TM, Manassass, VA, USA), human lung epithelial cells; MCF10A (ATCC® CRL-10317) human CF mammary epithelial cells; HaCaT (ATCC® CRL-2309), human keratinocytes; 16HBE14o- (16HBE, wt CFTR) and CFBE41o- (CFBE, homozygous for the CFTR Phe508del pathogenic variant), human bronchial epithelial cells kindly provided by Dr Dieter Gruenert [49]. The cell lines were cultured according to supplier’s specifications with minor modifications. Briefly, H441 cells were grown in complete RPMI-1640 medium (Gibco, Life Technologies, Foster City, CA, USA) supplemented with 10% FBS, MCF10A in a 1:1 mixture of DMEM (Euroclone) and Ham’s F12 (Gibco) supplemented with 10% FBS, 2 μg/mL bovine insulin, 2 ng/mL EGF (insulin and EGF were from Cambrex, East Rutherford, NJ, USA), HaCaT in DMEM (Euro-clone) supplemented with 10% FBS. 16HBE and CFBE cells were grown in MEM medium (Eagle’s Minimal Essential Medium) supplemented with 10% FBS, 2 mM Glutamine (medium and supplements were from Euroclone, Pero, Milan, Italy), and using plastics coated with fibronectin and collagen as previously reported [50]. In all cases a Penicillin–Streptomycin mixture (Euroclone), penicillin G 100 U/mL, streptomycin 0.1 mg/mL, was added to growth media; Fetal Bovine Serum was from Euroclone.
The cells were cultured at 37 °C under 5% CO2 and subculturing was performed according to the supplier’s specification; typically, on arrival the cells were expanded for no more than 10 passages and frozen in aliquots. When required, frozen stocks were thawed using standard procedure and used at passages 4–8 and never after the 10th passage. In no case sign of senescence were observed in growing cells.
When indicated, the cells were treated with 50 nM dexamethasone (Sigma-Aldrich, St. Louis, MO, USA) in culture medium for 6 h.
Nasal brushing from non-CF subjects were obtained by a sterile brush of 2.5 mm thickness.
Leukocytes were isolated from peripheral blood samples using LymphoPrep (Axis-Shield, Dundee, UK) according to the manufacturer’s instructions. In particular, lymphocytes and monocytes were isolated from the interphase of LymphoPrep, while granulocytes were recovered from the residual pellet. To separate lymphocytes from monocytes, an immunomagnetic method was used (Classical monocyte isolation kit, Miltenyi Biotech, Bergisch Gladbach, Germany).
Aliquots of cells and nasal brushing were stored either at −20 °C for DNA extraction or collected in 30 μL of RNA Later (Qiagen, Manchester, UK) and then stored at −80 °C for RNA extraction.
Nasal brushing and leukocytes used in this study were collected during institutional diagnostic procedures. The investigation described here could be carried out on residual specimens following diagnostic analysis with all data kept anonymous. Informed consent to the use was obtained.

4.2. RNA Extraction and Expression Analysis

Total RNA was extracted using RNeasy Mini Kit (Qiagen). The RNA samples were treated with DNase I to remove possible contaminating DNA before reverse transcription. For this, 1 μg RNA was treated with 0.4 units DNase I (New England Biolabs, Ipswich, MA, USA) at 37 °C for 10 min; the reaction was stopped by adding 50 mM EDTA at 75 °C for 10 min.
Both a qualitative endpoint PCR and a quantitative real time PCR was performed for the expression analyses of the SCNN1A, SCNN1B, SCNN1G, and CFTR genes, as described below.
For the qualitative endpoint PCR, the reverse transcription of 1 μg of RNA was performed using the iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA), according to the manufacturer’s instructions, in a PTC 100 (Biorad, Hercules, CA, USA) PCR system. As also previously described [51,52], the cDNA (2 μL out of 20 μL of the retrotranscription mix) was amplified, using 0.5 U of YieldAce Hotstart DNA polymerase (Stratagene, La Jolla, CA, USA), 175 μM of each dNTP, 1X YieldAce polymerase buffer and 6 pmol of each primer, in a final volume of 15 μL, according to the following PCR protocol: 2 min at 92 °C; from 30 to 40 cycles of 45 s at 94 °C, 1.5 min at 60 °C, 2.5 min at 72 °C; 7 min at 72 °C. The glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as housekeeping gene. See Table S1 for primers and details. Control PCR reactions included: NRTC (non-retrotranscribed control) in which the cDNA was substituted with total RNA, to identify possible amplification due to genomic DNA; NTC (no template control) containing all components except sample, to identify PCR contamination. Amplicons were analyzed by agarose gel electrophoresis, accompanied by a DNA ladder (GeneRuler 50 bp DNA Ladder, Thermo Scientific, Waltham, MA, USA) made up of 13 fragments with the following sizes (in base pairs): 1000, 900, 800, 700, 600, 500, 400, 300, 250, 200, 150, 100, 50. It contains two high concentration reference bands (500 and 250 bp) for easy orientation.
Quantitative real time PCR was performed using cDNA samples, retro-transcribed with the Reverse Trascription System kit (Promega, Fitchburg, WI, USA) and the PowerUp SYBR Green Master Mix (Applied Biosystems, Forster City, CA, USA) as previously reported [53]. Real time PCR was performed in the ABI7500 Real Time PCR system (Applied Biosystems, Forster City, CA, USA). For each target, the amplification conditions were optimized by running standard curves to ensure that all the targets were amplified with the same efficiency (higher than 95%); additionally, the most efficient concentration of primers was determined by running reactions with different primers concentrations, 300 nM, 600 nM and 900 nM each primer. From these preliminary settings we established the following PCR conditions: 2 μL of cDNA (out of 20 μL of the retrotranscription mix), 1X PowerUp SYBR Green PCR Master Mix (Applied Biosystems, Forster City, CA, USA), 600 nM forward and reverse primers, final volume 25 μL. PCR reactions were set up in triplicate in 96 multi-well plates; NRTC and NTC controls were also included. The cycling conditions were 2 min at 50 °C, 10 min at 95 °C; 40 cycles of 15 s at 95 °C, 1 min at 60 °C, with a final melting curve to control the specificity of amplification products. The β-actin was used as housekeeping gene. See Table S2 for primers and details. The relative quantification was calculated by the 2(−ΔΔCT) method, using the SCNN1B expression in CFBE as reference condition. Data are the mean of three independent experiments, each in triplicate.
The specificity and size of the amplicons obtained from qualitative and quantitative expression assays, were also verified by sequencing. For this, samples were run on agarose gels and amplicons were cut out and purified before applying a cycle sequencing protocol on an ABI PRISM 3130xl genetic analyzer (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA), using primers reported in Tables S1 and S2.

4.3. DNA Extraction and Methylation Analysis

Genomic DNA was extracted using QIAamp DNA Mini Kit (Qiagen). Quantification and purity were evaluated spectrophotometrically. DNA methylation was studied by a HpaII/PCR protocol as previously described [54,55]. Briefly, 1 μg of genomic DNA was treated with 3.5 U of the HpaII enzyme (New England Biolabs) in 1X NEBuffer at 37 °C overnight and with additional 2 U of the enzyme at 37 °C for further 6 h. Inactivation was achieved by treatment at 65 °C for 40 min. HpaII cuts CCGG sequence sites only if they are not methylated. After the enzymatic treatment, regions including the CCGG sites of interest were amplified by multiplex PCR starting from 5 ng of genomic digested DNA. The 5′-flanking regions of SCNN1A (2926 bp, 7 CCGG sites, 3 target regions, and 1 control region in 1 multiplex Hpa II/PCR), SCNN1B (3842 bp, 14 CCGG sites, 4 target regions, and 1 control region in 2 multiplex Hpa II/PCR) and SCNN1G (2537 bp, 21 CCGG sites, 2 target regions and 1 control region in 2 multiplex Hpa II/PCR) genes were studied. See Table S3 and Figure S4 for primers and details. The HpaII treated genomic DNA was amplified, using 0.5 U of YieldAce DNA polymerase and 1X YieldAce polymerase buffer (Stratagene), 175 μM of each dNTP, 6 pmol of each primer, in a final volume of 15 μL, in a PTC 100 (Biorad) PCR system according to the following touchdown protocol: 2 min at 92 °C; from 30 to 40 cycles of 45 s at 94 °C, 1.5 min starting from 66 °C with a reduction of the Ta of 0.1 °C per cycle, 2.5 min at 72 °C; 7 min at 72 °C.
The results were visualized by agarose gel electrophoresis, accompanied by a DNA ladder (GeneRuler 50 bp DNA Ladder, Thermo Scientific, Waltham, MA, USA), made up of 13 fragments with the following sizes (in base pairs): 1000, 900, 800, 700, 600, 500, 400, 300, 250, 200, 150, 100, 50. It contains two high concentration reference bands (500 and 250 bp) for easy orientation. The presence of the amplicon reveals a region with methylated site(s) (uncut by Hpa II), whereas its absence reveals a region with non-methylated site(s) (cut by Hpa II). The semiquantitative evaluation of the DNA methylation of the studied regions was performed by densitometric assay of amplicons, referred to the amplicon from a control uncut region (contained in each multiplex reaction).
For specificity evaluation and exact sizing, each amplicon (obtained in the Hpa II assay) was sequenced (after recovering from gel) by cycle sequencing on an ABI PRISM 3130xl genetic analyzer (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA), using primers reported in Table S3.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/ijms22073754/s1.

Author Contributions

Conceptualization, M.C., F.A. and M.L.; Data curation, S.P., G.T., F.C., P.D.P., S.M.B., S.C., M.C., F.A. and M.L.; Formal analysis, F.C., P.D.P., M.C., F.A. and M.L.; Funding acquisition, M.C., F.A. and M.L.; Investigation, S.P., G.T., F.C., P.D.P., S.M.B. and S.C.; Methodology, S.P., G.T., S.M.B. and S.C.; Project administration, M.L.; Resources, M.C., F.A. and M.L.; Supervision, S.P., M.C., F.A. and M.L.; Validation, S.P., G.T., F.C., P.D.P., S.M.B., S.C., M.C., F.A. and M.L.; Writing—original draft, M.C., F.A. and M.L.; Writing—review & editing, S.P., G.T., F.C., P.D.P., S.M.B., S.C., M.C., F.A. and M.L. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Italian Cystic Fibrosis Foundation (project FFC#3/2012), Lazio Region (CF research grants 2010 and 2011), Sapienza University of Rome (research grants 2011 and 2012).

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Sapienza University of Rome, protocol code 2581, date of approval 31 January 2013.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Data is contained within the article or Supplementary Materials.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

CFTRcystic fibrosis transmembrane conductance regulator
ENaCepithelial sodium channel
CFcystic fibrosis
SCNN1Asodium channel epithelial 1 subunit alpha
SCNN1Bsodium channel epithelial 1 subunit beta
SCNN1Gsodium channel epithelial 1 subunit gamma
CFTR-RDCFTR related disorders

References

  1. Lucarelli, M.; Bruno, S.M.; Pierandrei, S.; Ferraguti, G.; Stamato, A.; Narzi, F.; Amato, A.; Cimino, G.; Bertasi, S.; Quattrucci, S.; et al. A Genotypic-Oriented View of CFTR Genetics Highlights Specific Mutational Patterns Underlying Clinical Macrocategories of Cystic Fibrosis. Mol. Med. 2015, 21, 257–275. [Google Scholar] [CrossRef]
  2. Cutting, G.R. Cystic fibrosis genetics: From molecular understanding to clinical application. Nat. Rev. Genet. 2015, 16, 45–56. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Huber, R.; Krueger, B.; Diakov, A.; Korbmacher, J.; Haerteis, S.; Einsiedel, J.; Gmeiner, P.; Azad, A.K.; Cuppens, H.; Cassiman, J.-J.; et al. Functional Characterization of a Partial Loss-of-Function Mutation of the Epithelial Sodium Channel (ENaC) Associated with Atypical Cystic Fibrosis. Cell. Physiol. Biochem. 2010, 25, 145–158. [Google Scholar] [CrossRef] [PubMed]
  4. Sheridan, M.B.; Fong, P.; Groman, J.D.; Conrad, C.; Flume, P.; Diaz, R.; Harris, C.; Knowles, M.; Cutting, G.R. Mutations in the beta-subunit of the epithelial Na+ channel in patients with a cystic fibrosis-like syndrome. Hum. Mol. Genet. 2005, 14, 3493–3498. [Google Scholar] [CrossRef] [PubMed]
  5. Mutesa, L.; Azad, A.K.; Verhaeghe, C.; Segers, K.; Vanbellinghen, J.-F.; Ngendahayo, L.; Rusingiza, E.K.; Mutwa, P.R.; Rulisa, S.; Koulischer, L.; et al. Genetic Analysis of Rwandan Patients with Cystic Fibrosis-Like Symptoms. Chest 2009, 135, 1233–1242. [Google Scholar] [CrossRef] [PubMed]
  6. Azad, A.K.; Rauh, R.; Vermeulen, F.; Jaspers, M.; Korbmacher, J.; Boissier, B.; Bassinet, L.; Fichou, Y.; Georges, M.D.; Stanke, F.; et al. Mutations in the amiloride-sensitive epithelial sodium channel in patients with cystic fibrosis-like disease. Hum. Mutat. 2009, 30, 1093–1103. [Google Scholar] [CrossRef]
  7. Agrawal, P.B.; Wang, R.; Li, H.L.; Schmitz-Abe, K.; Simone-Roach, C.; Chen, J.; Shi, J.; Louie, T.; Sheng, S.; Towne, M.C.; et al. The Epithelial Sodium Channel Is a Modifier of the Long-Term Nonprogressive Phenotype Associated with F508del CFTR Mutations. Am. J. Respir. Cell Mol. Biol. 2017, 57, 711–720. [Google Scholar] [CrossRef]
  8. Zhou, Z.; Duerr, J.; Johannesson, B.; Schubert, S.C.; Treis, D.; Harm, M.; Graeber, S.Y.; Dalpke, A.; Schultz, C.; Mall, M.A. The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease. J. Cyst. Fibros. 2011, 10, S172–S182. [Google Scholar] [CrossRef] [Green Version]
  9. Rauh, R.; Hoerner, C. Korbmacher, deltabetagamma-ENaC is inhibited by CFTR but stimulated by cAMP in Xenopus laevis oocytes. Am. J. Physiol. Lung Cell Mol. Physiol. 2017, 312, 277–287. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Gentzsch, M.; Dang, H.; Dang, Y.; Garcia-Caballero, A.; Suchindran, H.; Boucher, R.C.; Stutts, M.J. The Cystic Fibrosis Transmembrane Conductance Regulator Impedes Proteolytic Stimulation of the Epithelial Na+ Channel. J. Biol. Chem. 2010, 285, 32227–32232. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Reddy, M.M.; Light, M.J.; Quinton, P.M. Activation of the epithelial Na+ channel (ENaC) requires CFTR Cl- channel function. Nat. Cell Biol. 1999, 402, 301–304. [Google Scholar] [CrossRef] [PubMed]
  12. Liu, Y.; Jiang, B.-J.; Zhao, R.-Z.; Ji, H.-L. Epithelial Sodium Channels in Pulmonary Epithelial Progenitor and Stem Cells. Int. J. Biol. Sci. 2016, 12, 1150–1154. [Google Scholar] [CrossRef] [Green Version]
  13. Hanukoglu, I.; Hanukoglu, A. Epithelial sodium channel (ENaC) family: Phylogeny, structure–function, tissue distribution, and associated inherited diseases. Gene 2016, 579, 95–132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Bangel, N.; Dahlhoff, C.; Sobczak, K.; Weber, W.-M.; Kusche-Vihrog, K. Upregulated expression of ENaC in human CF nasal epithelium. J. Cyst. Fibros. 2008, 7, 197–205. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Butterworth, M.B. Regulation of the epithelial sodium channel (ENaC) by membrane trafficking. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2010, 1802, 1166–1177. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Rubenstein, R.C.; Lockwood, S.R.; Lide, E.; Bauer, R.; Suaud, L.; Grumbach, Y. Regulation of endogenous ENaC functional expression by CFTR and DeltaF508-CFTR in airway epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2011, 300, 88–101. [Google Scholar] [CrossRef] [Green Version]
  17. Terlizzi, V.; Castaldo, G.; Salvatore, D.; Lucarelli, M.; Raia, V.; Angioni, A.; Carnovale, V.; Cirilli, N.; Casciaro, R.; Colombo, C.; et al. Genotype–phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles. J. Med. Genet. 2016, 54, 224–235. [Google Scholar] [CrossRef]
  18. Lucarelli, M.; Narzi, L.; Pierandrei, S.; Bruno, S.M.; Stamato, A.; D’Avanzo, M.; Strom, R.; Quattrucci, S. A new complex allele of the CFTR gene partially explains the variable phenotype of the L997F mutation. Genet. Med. 2010, 12, 548–555. [Google Scholar] [CrossRef] [Green Version]
  19. Cutting, G.R. Modifier genes in Mendelian disorders: The example of cystic fibrosis. Ann. N. Y. Acad. Sci. 2010, 1214, 57–69. [Google Scholar] [CrossRef]
  20. Corvol, H.; Blackman, S.M.; Boëlle, P.-Y.; Gallins, P.J.; Pace, R.G.; Stonebraker, J.R.; Accurso, F.J.; Clement, A.; Collaco, J.M.; Dang, H.; et al. Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. Nat. Commun. 2015, 6, 8382. [Google Scholar] [CrossRef] [Green Version]
  21. Lucarelli, M.; Porcaro, L.; Biffignandi, A.; Costantino, L.; Giannone, V.; Alberti, L.; Bruno, S.M.; Corbetta, C.; Torresani, E.; Colombo, C.; et al. A New Targeted CFTR Mutation Panel Based on Next-Generation Sequencing Technology. J. Mol. Diagn. 2017, 19, 788–800. [Google Scholar] [CrossRef] [Green Version]
  22. Lucarelli, M.; Bruno, S.M.; Pierandrei, S.; Ferraguti, G.; Testino, G.; Truglio, G.; Strom, R.; Quattrucci, S. The Impact on Genetic Testing of Mutational Patterns of CFTR Gene in Different Clinical Macrocategories of Cystic Fibrosis. J. Mol. Diagn. 2016, 18, 554–565. [Google Scholar] [CrossRef] [Green Version]
  23. Voilley, N.; Lingueglia, E.; Champigny, G.; Mattei, M.G.; Waldmann, R.; Lazdunski, M.; Barbry, P. The lung amiloride-sensitive Na+ channel: Biophysical properties, pharmacology, ontogenesis, and molecular cloning. Proc. Natl. Acad. Sci. USA 1994, 91, 247–251. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Voilley, N.; Bassilana, F.; Mignon, C.; Merscher, S.; Mattei, M.G.; Carle, G.F.; Lazdunski, M.; Barbry, P. Cloning, chromosomal localization, and physical linkage of the beta and gamma subunits (SCNN1B and SCNN1G) of the human epithelial amiloride-sensitive sodium channel. Genomics 1995, 28, 560–565. [Google Scholar] [CrossRef]
  25. Ludwig, M.; Bolkenius, U.; Wickert, L.; Marynen, P.; Bidlingmaier, F. Structural organisation of the gene encoding the α-subunit of the human amiloride-sensitive epithelial sodium channel. Qual. Life Res. 1998, 102, 576–581. [Google Scholar] [CrossRef] [PubMed]
  26. Thomas, C.P.; Loftus, R.W.; Liu, K.Z.; Itani, O.A. Genomic organization of the 5′ end of human beta-ENaC and preliminary characterization of its promoter. Am. J. Physiol. Renal Physiol. 2002, 282, 898–909. [Google Scholar] [CrossRef] [PubMed]
  27. Auerbach, S.D.; Loftus, R.W.; Itani, O.A.; Thomas, C.P. Human amiloride-sensitive epithelial Na+ channel gamma subunit promoter: Functional analysis and identification of a polypurine-polypyrimidine tract with the potential for triplex DNA formation. Biochem. J. 2000, 347, 105–114. [Google Scholar] [CrossRef]
  28. Zhang, L.N.; Karp, P.; Gerard, C.J.; Pastor, E.; Laux, D.; Munson, K.; Yan, Z.; Liu, X.; Godwin, S.; Thomas, C.P.; et al. Dual Therapeutic Utility of Proteasome Modulating Agents for Pharmaco-gene Therapy of the Cystic Fibrosis Airway. Mol. Ther. 2004, 10, 990–1002. [Google Scholar] [CrossRef]
  29. Peng, Y.; Wu, Q.; Wang, L.; Wang, H.; Yin, F. A DNA methylation signature to improve survival prediction of gastric cancer. Clin. Epigenetics 2020, 12, 1–16. [Google Scholar] [CrossRef] [Green Version]
  30. Qian, Y.; Wong, C.C.; Xu, J.; Chen, H.; Zhang, Y.; Kang, W.; Wang, H.; Zhang, L.; Li, W.; Chu, E.S.; et al. Sodium Channel Subunit SCNN1B Suppresses Gastric Cancer Growth and Metastasis via GRP78 Degradation. Cancer Res. 2017, 77, 1968–1982. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Zhong, Q.; Liu, C.; Fan, R.; Duan, S.; Xu, X.; Zhao, J.; Mao, S.; Zhu, W.; Hao, L.; Yin, F.; et al. Association of SCNN1B promoter methylation with essential hypertension. Mol. Med. Rep. 2016, 14, 5422–5428. [Google Scholar] [CrossRef]
  32. Edinger, R.S.; Yospin, J.; Perry, C.; Kleyman, T.R.; Johnson, J.P. Regulation of epithelial Na+ channels (ENaC) by methylation: A novel methyltransferase stimulates ENaC activity. J. Biol. Chem. 2006, 281, 9110–9117. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Mall, M.A.; Galietta, L.J. Targeting ion channels in cystic fibrosis. J. Cyst. Fibros. 2015, 14, 561–570. [Google Scholar] [CrossRef] [Green Version]
  34. Martin, S.L.; Saint-Criq, V.; Hwang, T.-C.; Csanády, L. Ion channels as targets to treat cystic fibrosis lung disease. J. Cyst. Fibros. 2018, 17, S22–S27. [Google Scholar] [CrossRef] [Green Version]
  35. Moore, P.J.; Tarran, R. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease. Expert Opin. Ther. Targets 2018, 22, 687–701. [Google Scholar] [CrossRef] [PubMed]
  36. Aarbiou, J.; Copreni, E.; Buijs-Offerman, R.M.; Van Der Wegen, P.; Castellani, S.; Carbone, A.; Tilesi, F.; Fradiani, P.; Hiemstra, P.S.; Yueksekdag, G.; et al. Lentiviral small hairpin RNA delivery reduces apical sodium channel activity in differentiated human airway epithelial cells. J. Gene Med. 2012, 14, 733–745. [Google Scholar] [CrossRef]
  37. Burrows, E.; Southern, K.W.; Noone, P. Sodium channel blockers for cystic fibrosis. Cochrane Database Syst. Rev. 2006, 3, CD005087. [Google Scholar]
  38. Zhou, Z.; Treis, D.; Schubert, S.C.; Harm, M.; Schatterny, J.; Hirtz, S.; Duerr, J.; Boucher, R.C.; Mall, M.A. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice. Am. J. Respir. Crit. Care Med. 2008, 178, 1245–1256. [Google Scholar] [CrossRef] [PubMed]
  39. Manunta, M.D.I.; Tagalakis, A.D.; Attwood, M.; Aldossary, A.M.; Barnes, J.L.; Munye, M.M.; Weng, A.; McAnulty, R.J.; Hart, S.L. Delivery of ENaC siRNA to epithelial cells mediated by a targeted nanocomplex: A therapeutic strategy for cystic fibrosis. Sci. Rep. 2017, 7, 1–12. [Google Scholar] [CrossRef] [Green Version]
  40. Crosby, J.R.; Zhao, C.; Jiang, C.; Bai, D.; Katz, M.; Greenlee, S.; Kawabe, H.; McCaleb, M.; Rotin, D.; Guo, S.; et al. Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice. J. Cyst. Fibros. 2017, 16, 671–680. [Google Scholar] [CrossRef] [Green Version]
  41. Scott, D.W.; Walker, M.P.; Sesma, J.; Wu, B.; Stuhlmiller, T.J.; Sabater, J.R.; Abraham, W.M.; Crowder, T.M.; Christensen, D.J.; Tarran, R. SPX-101 Is a Novel Epithelial Sodium Channel–targeted Therapeutic for Cystic Fibrosis That Restores Mucus Transport. Am. J. Respir. Crit. Care Med. 2017, 196, 734–744. [Google Scholar] [CrossRef]
  42. Coote, K.; Atherton-Watson, H.C.; Sugar, R.; Young, A.; MacKenzie-Beevor, A.; Gosling, M.; Bhalay, G.; Bloomfield, G.; Dunstan, A.; Bridges, R.J.; et al. Camostat Attenuates Airway Epithelial Sodium Channel Function in Vivo through the Inhibition of a Channel-Activating Protease. J. Pharmacol. Exp. Ther. 2009, 329, 764–774. [Google Scholar] [CrossRef] [Green Version]
  43. Shei, R.-J.; Peabody, J.E.; Kaza, N.; Rowe, S.M. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis. Curr. Opin. Pharmacol. 2018, 43, 152–165. [Google Scholar] [CrossRef] [PubMed]
  44. Murabito, A.; Ghigo, A. Inhaled Biologicals for the Treatment of Cystic Fibrosis. Recent Pat. Inflamm. Allergy Drug Discov. 2019, 13, 19–26. [Google Scholar] [CrossRef]
  45. Mroz, M.S.; Harvey, B.J. Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fibrosis bronchial epithelial cells. Steroids 2019, 151, 108461. [Google Scholar] [CrossRef] [PubMed]
  46. Lucarelli, M.; Ferraguti, G.; Fuso, A. Active Demethylation of Non-CpG Moieties in Animals: A Neglected Research Area. Int. J. Mol. Sci. 2019, 20, 6272. [Google Scholar] [CrossRef] [Green Version]
  47. Fuso, A.; Ferraguti, G.; Grandoni, F.; Ruggeri, R.; Scarpa, S.; Strom, R.; Lucarelli, M. Early demethylation of non-CpG, CpC-rich, elements in the myogenin 5′-flanking region: A priming effect on the spreading of active demethylation. Cell Cycle 2010, 9, 3965–3976. [Google Scholar] [CrossRef] [Green Version]
  48. Monti, N.; Cavallaro, R.A.; Stoccoro, A.; Nicolia, V.; Scarpa, S.; Kovacs, G.G.; Fiorenza, M.T.; Lucarelli, M.; Aronica, E.; Ferrer, I.; et al. CpG and non-CpG Presenilin1 methylation pattern in course of neurodevelopment and neurodegeneration is associated with gene expression in human and murine brain. Epigenetics 2020, 15, 781–799. [Google Scholar] [CrossRef] [Green Version]
  49. Gruenert, D.C.; Willems, M.; Cassiman, J.J.; Frizzell, R.A. Established cell lines used in cystic fibrosis re-search. J. Cyst. Fibros. 2004, 3, 191–196. [Google Scholar] [CrossRef] [Green Version]
  50. De Rocco, D.; Pompili, B.; Castellani, S.; Morini, E.; Cavinato, L.; Cimino, G.; Mariggiò, M.A.; Guarnieri, S.; Conese, M.; Del Porto, P.; et al. Assembly and Functional Analysis of an S/MAR Based Episome with the Cystic Fibrosis Transmembrane Conductance Regulator Gene. Int. J. Mol. Sci. 2018, 19, 1220. [Google Scholar] [CrossRef] [Green Version]
  51. Auriche, C.; Carpani, D.; Conese, M.; Caci, E.; Zegarra-Moran, O.; Donini, P.; Ascenzioni, F. Functional human CFTR produced by a stable minichromosome. EMBO Rep. 2002, 3, 862–868. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Auriche, C.; Di Domenico, E.G.; Pierandrei, S.; Lucarelli, M.; Castellani, S.; Conese, M.; Melani, R.; Zegarra-Moran, O.; Ascenzioni, F. CFTR expression and activity from the human CFTR locus in BAC vectors, with regulatory regions, isolated by a single-step procedure. Gene Ther. 2010, 17, 1341–1354. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Luly, F.R.; Lévêque, M.; Licursi, V.; Cimino, G.; Martin-Chouly, C.; Théret, N.; Negri, R.; Cavinato, L.; Ascenzioni, F.; Del Porto, P. MiR-146a is over-expressed and controls IL-6 production in cystic fibrosis macrophages. Sci. Rep. 2019, 9, 1–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Fuso, A.; Scarpa, S.; Grandoni, F.; Strom, R.; Lucarelli, M. A reassessment of semiquantitative analytical procedures for DNA methylation: Comparison of bisulfite- and HpaII polymerase-chain-reaction-based methods. Anal. Biochem. 2006, 350, 24–31. [Google Scholar] [CrossRef] [PubMed]
  55. Lucarelli, M.; Fuso, A.; Strom, R.; Scarpa, S. The Dynamics of Myogenin Site-specific Demethylation Is Strongly Correlated with Its Expression and with Muscle Differentiation. J. Biol. Chem. 2001, 276, 7500–7506. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Ijms 22 03754 g001 550
Figure 1. Expression analysis of ENaC genes by real time PCR. Results represent the expression of SCNN1A (A–C), SCNN1B (D–F) and SCNN1G (G–I) genes in H441, MCF10A, 16HBE, CFBE, HaCaT cell lines (respectively from 1 to 5, panels A,D,G), H441 and MCF10A with (+) and without (−) dexamethasone treatment (panels B,E,H) and nasal brushing (B), lymphocytes/monocytes (LM), granulocytes (PMN), lymphocytes (L), monocytes (M) (respectively from 6 to 10, panels (C,F,I)). A relative quantification (RQ) is reported on y-axis, as fold changes in respect to SCNN1B expression in CFBE (panel (D), column 4) used as reference condition (the numbers above the bars are the exact RQ values). For panels (A,C,D,F,G,I), ANOVA p < 0.01; for panels (C,D,F,I) the single * indicates the only statistically significant difference in the panel following Bonferroni’s multiple comparison test (* p < 0.01); for panels (A) and (G) the statistically significant differences between specific conditions following Bonferroni’s multiple comparison test are as indicated (* p < 0.01). For panels (B,E,H), Student’s t-test of all dexamethasone treated cells (+) as compared to respective untreated cells (−) * p < 0.01.
Figure 1. Expression analysis of ENaC genes by real time PCR. Results represent the expression of SCNN1A (A–C), SCNN1B (D–F) and SCNN1G (G–I) genes in H441, MCF10A, 16HBE, CFBE, HaCaT cell lines (respectively from 1 to 5, panels A,D,G), H441 and MCF10A with (+) and without (−) dexamethasone treatment (panels B,E,H) and nasal brushing (B), lymphocytes/monocytes (LM), granulocytes (PMN), lymphocytes (L), monocytes (M) (respectively from 6 to 10, panels (C,F,I)). A relative quantification (RQ) is reported on y-axis, as fold changes in respect to SCNN1B expression in CFBE (panel (D), column 4) used as reference condition (the numbers above the bars are the exact RQ values). For panels (A,C,D,F,G,I), ANOVA p < 0.01; for panels (C,D,F,I) the single * indicates the only statistically significant difference in the panel following Bonferroni’s multiple comparison test (* p < 0.01); for panels (A) and (G) the statistically significant differences between specific conditions following Bonferroni’s multiple comparison test are as indicated (* p < 0.01). For panels (B,E,H), Student’s t-test of all dexamethasone treated cells (+) as compared to respective untreated cells (−) * p < 0.01.
Ijms 22 03754 g001
Ijms 22 03754 g002 550
Figure 2. Methylation analysis of 5′-flanking region of SCNN1A gene by Hpa II/PCR. Results represent products of PCR amplification after HpaII enzymatic treatment of indicated cell lines (1–5, panel (A)), H441 and MCF10A with (+) and without (−) dexamethasone treatment (1, 2; panel (B)) and ex vivo samples (6–10, panel (C)). Each sample was tested at different cycles of PCR amplification protocol, as indicated for panels on the left and on the right of the figure, to better highlight the differences. The analyzed regions are indicated as a, b, c and Control (with the size of amplicons indicated in base pairs (bp) in lower panels). In every panel: 1 = H441, 2 = MCF10A, 3 = 16HBE, 4 = CFBE, 5 = HaCaT, 6 = nasal brushing, 7 = lymphocytes + monocytes, 8 = granulocytes, 9 = lymphocytes, 10 = monocytes. The first and last lane of each panel contain the DNA ladder described in Materials and Methods.
Figure 2. Methylation analysis of 5′-flanking region of SCNN1A gene by Hpa II/PCR. Results represent products of PCR amplification after HpaII enzymatic treatment of indicated cell lines (1–5, panel (A)), H441 and MCF10A with (+) and without (−) dexamethasone treatment (1, 2; panel (B)) and ex vivo samples (6–10, panel (C)). Each sample was tested at different cycles of PCR amplification protocol, as indicated for panels on the left and on the right of the figure, to better highlight the differences. The analyzed regions are indicated as a, b, c and Control (with the size of amplicons indicated in base pairs (bp) in lower panels). In every panel: 1 = H441, 2 = MCF10A, 3 = 16HBE, 4 = CFBE, 5 = HaCaT, 6 = nasal brushing, 7 = lymphocytes + monocytes, 8 = granulocytes, 9 = lymphocytes, 10 = monocytes. The first and last lane of each panel contain the DNA ladder described in Materials and Methods.
Ijms 22 03754 g002
Ijms 22 03754 g003 550
Figure 3. Methylation analysis of 5′-flanking region of SCNN1B gene by Hpa II/PCR. Results represent products of PCR amplification after HpaII enzymatic treatment of indicated cell lines (1–5, panels (A,D)), H441 and MCF10A with (+) and without (−) dexamethasone treatment (1, 2; panels (B,E)) and ex vivo samples (6–10, panels (C,F)). Each sample was tested at different cycles of PCR amplification protocol, as indicated for panels on the left and on the right of the figure, to better highlight the differences. The analyzed regions are indicated as a, b, c, d and Control (with the size of amplicons indicated in base pairs (bp) in lower panels). In every panel: 1 = H441, 2 = MCF10A, 3 = 16HBE, 4 = CFBE, 5 = HaCaT, 6 = nasal brushing, 7 = lymphocytes + monocytes, 8 = granulocytes, 9 = lymphocytes, 10 = monocytes. The first and last lane of each panel contain the DNA ladder described in Materials and Methods.
Figure 3. Methylation analysis of 5′-flanking region of SCNN1B gene by Hpa II/PCR. Results represent products of PCR amplification after HpaII enzymatic treatment of indicated cell lines (1–5, panels (A,D)), H441 and MCF10A with (+) and without (−) dexamethasone treatment (1, 2; panels (B,E)) and ex vivo samples (6–10, panels (C,F)). Each sample was tested at different cycles of PCR amplification protocol, as indicated for panels on the left and on the right of the figure, to better highlight the differences. The analyzed regions are indicated as a, b, c, d and Control (with the size of amplicons indicated in base pairs (bp) in lower panels). In every panel: 1 = H441, 2 = MCF10A, 3 = 16HBE, 4 = CFBE, 5 = HaCaT, 6 = nasal brushing, 7 = lymphocytes + monocytes, 8 = granulocytes, 9 = lymphocytes, 10 = monocytes. The first and last lane of each panel contain the DNA ladder described in Materials and Methods.
Ijms 22 03754 g003
Ijms 22 03754 g004 550
Figure 4. Methylation analysis of 5′-flanking region of SCNN1G gene by HpaII/PCR. Results represent products of PCR amplification after HpaII enzymatic treatment of indicated cell lines (1–5, panels (A,D)), H441 and MCF10A with (+) and without (−) dexamethasone treatment (1, 2; panels (B,E)) and ex vivo samples (6–10, panels (C,F)). Each sample was tested at different cycles of PCR amplification protocol, as indicated for panels on the left and on the right of the figure, to better highlight the differences. The analyzed regions are indicated as a, b, and Control (with the size of amplicons indicated in base pairs (bp) in lower panels). In every panel: 1 = H441, 2 = MCF10A, 3 = 16HBE, 4 = CFBE, 5 = HaCaT, 6 = nasal brushing, 7 = lymphocytes + monocytes, 8 = granulocytes, 9 = lymphocytes, 10 = monocytes. The first and last lane of each panel contain the DNA ladder described in Materials and Methods.
Figure 4. Methylation analysis of 5′-flanking region of SCNN1G gene by HpaII/PCR. Results represent products of PCR amplification after HpaII enzymatic treatment of indicated cell lines (1–5, panels (A,D)), H441 and MCF10A with (+) and without (−) dexamethasone treatment (1, 2; panels (B,E)) and ex vivo samples (6–10, panels (C,F)). Each sample was tested at different cycles of PCR amplification protocol, as indicated for panels on the left and on the right of the figure, to better highlight the differences. The analyzed regions are indicated as a, b, and Control (with the size of amplicons indicated in base pairs (bp) in lower panels). In every panel: 1 = H441, 2 = MCF10A, 3 = 16HBE, 4 = CFBE, 5 = HaCaT, 6 = nasal brushing, 7 = lymphocytes + monocytes, 8 = granulocytes, 9 = lymphocytes, 10 = monocytes. The first and last lane of each panel contain the DNA ladder described in Materials and Methods.
Ijms 22 03754 g004
Ijms 22 03754 g005 550
Figure 5. Schematic representation of results about methylation and expression profiles of ENaC genes. The profiles of methylation and expression are indicated for cell lines (1–5), H441 and MCF10A (1, 2) with (+) and without (−) dexamethasone treatment, and for ex vivo samples (6–10), as annotated in the legends. Squares represent DNA methylation levels (empty square: unmethylated; half-filled square: partially methylated; filled square: methylated). Triangles represent expression levels (the number of triangles is proportional to the level of expression; no triangle: expression undetectable; one or two triangles: low expression; five to seven triangles: high expression; more than eleven triangles: very high expression). (A) Results of the SCNN1A gene. a, b, c = methylation analysis regions. (B) Results of the SCNN1B gene. a, b, c, d = methylation analysis regions. (C) Results of the SCNN1G gene. a, b = methylation analysis regions.
Figure 5. Schematic representation of results about methylation and expression profiles of ENaC genes. The profiles of methylation and expression are indicated for cell lines (1–5), H441 and MCF10A (1, 2) with (+) and without (−) dexamethasone treatment, and for ex vivo samples (6–10), as annotated in the legends. Squares represent DNA methylation levels (empty square: unmethylated; half-filled square: partially methylated; filled square: methylated). Triangles represent expression levels (the number of triangles is proportional to the level of expression; no triangle: expression undetectable; one or two triangles: low expression; five to seven triangles: high expression; more than eleven triangles: very high expression). (A) Results of the SCNN1A gene. a, b, c = methylation analysis regions. (B) Results of the SCNN1B gene. a, b, c, d = methylation analysis regions. (C) Results of the SCNN1G gene. a, b = methylation analysis regions.
Ijms 22 03754 g005
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Pierandrei, S.; Truglio, G.; Ceci, F.; Del Porto, P.; Bruno, S.M.; Castellani, S.; Conese, M.; Ascenzioni, F.; Lucarelli, M. DNA Methylation Patterns Correlate with the Expression of SCNN1A, SCNN1B, and SCNN1G (Epithelial Sodium Channel, ENaC) Genes. Int. J. Mol. Sci. 2021, 22, 3754. https://doi.org/10.3390/ijms22073754

AMA Style

Pierandrei S, Truglio G, Ceci F, Del Porto P, Bruno SM, Castellani S, Conese M, Ascenzioni F, Lucarelli M. DNA Methylation Patterns Correlate with the Expression of SCNN1A, SCNN1B, and SCNN1G (Epithelial Sodium Channel, ENaC) Genes. International Journal of Molecular Sciences. 2021; 22(7):3754. https://doi.org/10.3390/ijms22073754

Chicago/Turabian Style

Pierandrei, Silvia, Gessica Truglio, Fabrizio Ceci, Paola Del Porto, Sabina Maria Bruno, Stefano Castellani, Massimo Conese, Fiorentina Ascenzioni, and Marco Lucarelli. 2021. "DNA Methylation Patterns Correlate with the Expression of SCNN1A, SCNN1B, and SCNN1G (Epithelial Sodium Channel, ENaC) Genes" International Journal of Molecular Sciences 22, no. 7: 3754. https://doi.org/10.3390/ijms22073754

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop